Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics Publication Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics Perhaps the most important lesson learned from the COVID‐19 pandemic is that of preparedness. Enhanced…Jim Gallagher2021年5月11日
Purity is a Virtue: A Practical Guide to the Reporting of Impurities On-Demand Webinar Purity is a Virtue: 不純物報告に関する実践ガイド Many pharmaceutical companies struggle with characterizing drug substance (DS) and drug product (DP) impurities and…Certara2021年3月23日
Optimize Immuno-oncology Drug Discovery and Development Using QSP White Paper がん免疫療法の創薬と開発をQSPで最適化 A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…webdev2019年6月19日
7 Things to Know About the China Pharmaceutical Industry Blog 7 Things to Know About the China Pharmaceutical Industry China is the second largest pharmaceutical market in the world. Demand is likely to increase…Certara2018年10月16日
Pharmacokinetic/ Toxicokinetic Services Brochure Pharmacokinetic/ Toxicokinetic Services As your partner for drug development and regulatory strategy, Certara has expanded its services to…webdev2018年5月18日
Changing the Game in Drug Development Brochure 医薬品開発の大変革 At Certara, we are innovators, dedicated to helping our clients develop new therapies and target…webdev2018年3月19日
Abundance of Hepatic Transporters in Caucasians: A Meta-analysis Publication Abundance of Hepatic Transporters in Caucasians: A Meta-analysis The aim of this study was to derive quantitative abundance values for key hepatic transporters…webdev2016年10月1日
Rare Disease and Orphan Drug Development Brochure 希少疾病と希少疾病用医薬品の開発 There are 7,000 rare diseases impacting 350 million patients worldwide, yet only 300 of these…webdev2016年8月3日
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances Publication More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances Rosuvastatin is a substrate of choice in clinical studies of organic anion-transporting polypeptide (OATP)1B1- and…webdev2016年7月1日
Development of a Permeability-limited Model of the Human Brain and Cerebrospinal Fluid (CSF) to Integrate Known Physiological and Biological Knowledge: Estimating Time Varying CSF Drug Concentrations and Their Variability Using In Vitro Data Publication Development of a Permeability-limited Model of the Human Brain and Cerebrospinal Fluid (CSF) to Integrate Known Physiological and Biological Knowledge: Estimating Time Varying CSF Drug Concentrations and Their Variability Using In Vitro Data A 4-compartment permeability-limited brain (4Brain) model consisting of brain blood, brain mass, cranial and spinal…webdev2016年6月1日